Novocure (NVCR) Misses Q4 EPS by 4c, Revenues Miss

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. TSLA
6. META
7. RTX
8. SMCI
9. GOOGL
10. S

Go back to Novocure (NVCR) Misses Q4 EPS by 4c, Revenues Miss

Novocure Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Company Update

February 28, 2019 6:00 AM EST

Quarterly net revenues of $69.7 million, representing 30 percent growth versus the fourth quarter 2017 and 8 percent growth versus the third quarter 2018

Full year 2018 net revenues of $248.1 million, representing annual growth of 40 percent compared to 2017

Three additional phase 3 clinical trials ongoing studying the use of Optune in brain metastases, non-small-cell lung cancer and pancreatic cancer

ST. HELIER, Jersey--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) today reported financial results for the quarter and year ended December 31, 2018, highlighting continued revenue growth, anticipated clinical and regulatory milestones and a strong cash position.... More